Low IGFBP7 expression identifies a subset of breast cancers with favorable prognosis and sensitivity to IGF-1 receptor targeting with ganitumab: Data from I-SPY2 and SCAN-B

Introduction

A significant portion of breast cancer patients relapse despite receiving optimal treatment adjuvant or neoadjuvant according to current guidelines ¹. This fact highlights the need for new treatments and new biomarkers to better guide patient selection.

Dysregulation of insulin-like growth factor-1 receptor (IGF-1R) signaling has long been correlated with breast cancer growth, proliferation, and survival ^2,3. Many agents have been developed to target IGF-1R ⁴. To date, no studies have demonstrated a substantial clinical benefit of adding IGF-1R targeting agents to existing treatments ⁴. A possible explanation is that response to chemotherapy is enhanced by IGF-IR targeting only in a subset of tumors, following the well-known precedent that adding HER2 targeting agents to chemotherapy is only helpful in HER2-positive tumors ^5–7. However, no predictive biomarkers for IGF-IR targeting agents have been identified.

Recently, the Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2 (I-SPY2) trial showed a small increase in pathological complete response (pCR) rate when the anti IGF-1R monoclonal antibody ganitumab (AMG479) (given with metformin to reduced treatment-induced hyperglycemia) was added to chemotherapy, but the effect size failed to reach the prespecified threshold for a positive result ⁸. Further, eleven putative IGF-1R signaling axis biomarkers were tested, but none were predictive of ganitumab benefit ⁸.

I-SPY2 has been able to identify treatment predictive biomarkers for emerging treatments due to its unique design^9–12, and to evaluate efficacy of new treatments^13–16. To further this goal, the I-SPY2-990 Data Resource has been made publicly available¹³.

It has previously been shown¹⁷that unlike other IGFBPs, IGFBP7 can bind to the IGF-1R-, but the in vivo consequences of the IGFBP7 - IGF-1R interaction are unclear. There are also gaps in knowledge concerning complex interactions between IGFBP7 and IGF-1R in the presence of anti-IGF-1R antibodies such as Ganitumab. IGFBP7 binds insulin-like growth factor-1 (IGF-1) and the IGF-1R in a mutually exclusive manner¹⁷. Compared to other IGFBPs, IGFBP7 binds insulin with higher affinity than IGFs ^17,18. The binding of IGFBP7 decreases activation and internalization of IGF-1R in response to IGF-1/2 but at the same time sensitizes IGF-1R to insulin stimulation ^17,18. IGFBP7 was shown to prolong the surface retention of the IGF-1R under insulin/IGF1 stimulation resulting in prolonged IGF-1R signaling in leukemia ¹⁸. It also has been shown that IGFBP7 promotes the persistence of IGF-1R at the cell surface, prolonging insulin/IGF stimulation, and enhancing Akt activation leading to mitogenic and pro-survival effects ^18,19.

Although we have presented prior evidence that high IGFBP7 expression by breast cancer tissue or high circulating levels of this protein are related to poor prognosis ^20,21, this protein has not previously been studied in relation to efficacy of IGF-1R targeted therapies. We previously reported that the prognostic value of circulating IGFBP7 was only seen for patients who had cancers with positive IGF-1R membrane status ²¹, which suggested that the interplay between IGFBP7 and IGF-1R merits further investigation. We hypothesized that IGFBP7 might compete with IGF-1R monoclonal antibody binding to IGF-1R, decreasing its efficacy and at the same time promoting tumor growth and metastatic potential.

Materials and methods

I-SPY2

The I-SPY2 trial (NCT01042379) is an open-label, multicenter, adaptively randomized phase 2 trial of neoadjuvant therapy, evaluating multiple investigational arms in parallel. Neoadjuvant paclitaxel followed by doxorubicin/cyclophosphamide (with Trastuzumab in HER2+ disease) serves as the common control arm ^15,16. Investigational agent(s) are combined with this regimen ^15,16. The primary endpoint is pCR (ypT0/is, ypN0) ^15,16. Eligibility for I-SPY2 includes age 18 years or older, stage II or III breast cancer and primary tumor size >2.5 cm by clinical examination or >2.0 cm by imaging ^15,16Patients with hormone receptor (HR)+ cancers are eligible only if they have a poor prognosis estimated by the MammaPrint (MP) 70-gene based prognostic signature¹³. Subsequent adjuvant endocrine treatment was at the discretion of the treating physician. Ganitumab was tested in combination with metformin since ganitumab can induce hyperglycemia ⁸. In the I-SPY2 study of the IGF-IR blocking antibody ganitumab, patients with HER2+ tumors were not included since there is no safety data concerning the combination of ganitumab and trastuzumab ⁸. Gene expression profiling of core needle biopsies taken from the primary tumor before treatment was performed using Agilent 44K expression arrays ¹³. Transcriptomic and clinical data of patients enrolled in the I-SPY2 trial were obtained from the Gene Expression Omnibus (GEO) database (GSE194040). For the analysis reported here, we studied patients from the ganitumab/metformin plus chemotherapy arm and the chemotherapy-alone control arm, excluding patients with HER2+ disease (Figure 1).

• Download figure
• Open in new tab

Figure 1.

Flowchart of included and excluded patients in I-SPY2. pCR rates in the ganitumab/metformin plus chemotherapy arm and chemotherapy control arm, according to IGFBP7 expression categories.

Results

Figure 1 summarizes the pCR rates in patient subsets across the I-SPY2 trial. In all patients (across all treatment arms), IGFBP7 (continuous and in quartiles) expression was not associated with odds of achieving pCR in the multivariable model (Supplementary Table 1). Descriptive statistics for clinicopathological factors are presented in Table 1, Supplementary Table 2 for I-SPY2. There was an interaction between IGFBP7 expression (continuous and in quartiles) and efficacy of ganitumab/metformin plus chemotherapy treatment in achieving pCR in both the crude (LR P=0.011 for both continuous and quartiles) and multivariable models (LR P=0.017 for continuous and LR P=0.015 for quartiles) (Table 2). In the ganitumab/metformin plus chemotherapy arm 22.6% of patients achieved pCR compared to 16.8% in the chemotherapy alone control arm. However, higher IGFBP7 expression conferred lower odds of achieving pCR in the ganitumab/metformin plus chemotherapy arm, adjusted OR 0.38 (95% CI 0.17–0.80) but not in the chemotherapy alone control arm, adjusted OR 1.23 (95% CI 0.63–2.45; P_interaction=0.016) (Figures 1-2 and Table 2). Likewise, Q2-4 of IGFBP7 expression compared to Q1 also conferred lower odds of achieving pCR in the ganitumab/metformin plus chemotherapy arm (Q4 adjusted OR 0.09 (95% CI 0.00–0.58)) but not in the chemotherapy-alone control arm (adjusted OR 1.38 (95% CI 0.41–4.73; P_interaction=0.031)) The crude and adjusted ORs for Q2-3 and other clinicopathological factors are provided in Figure 1 and Table 2. When stratified by quartiles, in the ganitumab/metformin plus chemotherapy arm 46.9% of IGFBP7 Q1 tumors achieved pCR compared to 17.2% of IGFBP7 Q2 tumors, 11.5% of IGFBP7 Q3 tumors, and only 5.6% of IGFBP7 Q4 tumors (Figure 2B and Table 2). In the chemotherapy alone control arm, 14.0% IGFBP7 Q1 tumors, 20.0% of IGFBP7 Q2 tumors, 16.7% IGFBP7 Q3 tumors, and 16.3% of IGFBP7 Q4 tumors achieved pCR (Figure 1, Figure 2C and Table 2). When divided by breast cancer subtype (high risk HR+HER2-vs. TNBC), the ability of IGFBP7 expression to identify breast cancers more likely to respond to ganitumab/metformin plus chemotherapy than to chemotherapy alone, was more apparent in TNBC, where 66.7% of IGFBP7 Q1 tumors and no IGFBP7 Q4 tumors achieved pCR, but the numbers are too small to draw definitive conclusions (Table 3). In an exploratory analysis, stratified by IGFBP7 expression quartiles, ganitumab/metformin plus chemotherapy treatment conferred higher odds of achieving pCR in tumors with low IGFBP7 expression (Q1-2) (adjusted OR 2.64 (95% CI 1.16–5.49)) but not in in tumors with high IGFBP7 expression (Q3-4), (adjusted OR 0.44 (95% CI 0.11–1.40)). The improved efficacy of ganitumab/metformin plus chemotherapy treatment compared to standard chemotherapy in achieving pCR was confined to the ≈ 25% of patients in the lowest quartile of IGFB7 expression, where the pCR rate was 46.9% in the ganitumab/metformin plus chemotherapy group, compared to 14% in the chemotherapy alone group (Figure 1 and Table 4).

• Download figure
• Open in new tab

Figure 2.

IGFBP7 expression in relation to pCR Heatmap of differentially expressed genes (DEG) in IGFBP7 Q4 compared to in IGFBP7 Q1 tumors in (A) I-SPY2. Patients are along columns and biomarkers are along the rows. Red indicates higher expression and blue lower. Annotation tracks reflect pCR (purple), Receptor Subtype, PAM50 subtype, and trial arm (light red: ganitumab/metformin plus chemotherapy). IGFBP7 expression (continuous) by pCR in (B) the ganitumab/metformin plus chemotherapy arm and in (C) the control arm. pCR rate by IGFBP7 quartiles in (D) the ganitumab/metformin plus chemotherapy arm and in (E) the control arm.

In SCAN-B, the median follow-up for the 4158 patients still at risk was 5.45 (inter quartile range 5.07–8.15) years and descriptive statistics are presented in Supplementary Table 3 for SCAN-B. In the univariable survival analyses of IGFBP7 expression in the SCAN-B cohort, IGFBP7 expression Q4 compared to Q1 was not associated with increased risk of recurrence (HR 0.96 (95% CI 0.76–1.22)) or distant metastasis (HR 1.00 (95% CI 0.77–1.32)) (Supplementary Table 4). However, after adjustment for age, clinicopathological factors and treatment in the multivariable models, high IGFBP7 expression (Q4 compared to Q1) was associated with significantly increased risk of recurrence (HR 1.37 (95% CI 1.04–1.82)) and distant metastasis (HR 1.60 (95% CI 1.15–2.22)) (Supplementary Table 4). When modeled as a continuous variable, IGFBP7 expression showed similar associations with clinical outcome (Supplementary Table 5). Most importantly, IGFBP7 (continuous) gene expression in the adjusted model also conferred a significantly increased risk of recurrence (HR 1.29 (95% CI 1.09–1.53)) and distant metastasis (HR 1.41 (95% CI 1.16–1.73)) (Supplementary Table 5).

Having demonstrated that low IGFBP7 expression is predictive of a benefit of adding ganitumab to chemotherapy in neoadjuvant breast cancer treatment, we sought to determine if IGFBP7 expression was related to other breast cancer characteristics. In both ISPY-2 and SCAN-B, IGFBP7 expression was positively correlated with IGFBP3-6 and IGF1 and IGF2 expression (all r_s ≥0.14) (Supplementary Figure 2 A-B). IGFBP7 expression was highest in Normal-like followed by Luminal A subtype in both the ISPY-2 trial and SCAN-B cohort (Supplementary Figure 2 C-D). Likewise, the correlations between IGFBP7 expression and the eight gene modules were similar in ISPY-2 and SCAN-B. IGFBP7 expression was positively correlated with stroma, lipid, and early response to growth signaling modules and negatively correlated with mitotic checkpoint and progression modules (Supplementary Figure 2 E-F). The correlations suggest an association with aggressive tumor microenvironment (TME) and increased growth factor signaling activation. IGFBP7 expression did not vary across HR-positive and HER2-positive subtypes (Supplementary Figure 2 G-H).

Differential gene expression (DGE) analyses were performed comparing IGFBP7 Q4 versus Q1 tumors in I-SPY2 and SCAN-B. Notably, higher expression of several genes coding for proteins involved in endothelial cell regulation and extracellular matrix remodeling, e.g. PDGFRB, COMP, FAP, COL1A1, OGN, LUM, COL3A1, SPOCK1, COL1A2, DCN, ANGPTL1, and SPON1 were seen in IGFBP7 Q4 tumors, supporting a potential association with an active TME (Figure 2-3 and Supplementary Tables 6-7). Significantly enriched gene sets in IGFBP7 Q4 tumors included EMT and TGF-β signaling (Figure 3 and Supplementary Tables 8-9). Tumor tissue composition was estimated by ECOTYPER²⁹. High IGFBP7 gene expression (continuous and in quartiles) was associated with dominance of Carcinoma Ecotype (CE) 6, CE 1, followed by CE 10 (P<0.001; Figure 4). This indicates that tumors with high IGFBP7 gene expression have a microenvironment enriched for stromal cells while deficient in immune cells, characterized by transforming growth factor beta signaling (Figure 4). Conversely, tumors with low IGFBP7 gene expression (continuous and in quartiles) were dominated by CE 2 and CE 9, indicating basal-like features and a pro-inflammatory response (Figure 4).

• Download figure
• Open in new tab

Figure 3.

Molecular analyses of IGFBP7 expression in I-SPY2 and SCAN-B Volcano plots showing significantly up- and downregulated genes in IGFBP7 Q4 compared to in IGFBP7 Q1 tumors in (A) I-SPY2, and (B) SCAN-B. Dot plots showing activated and suppressed Hallmark Signatures in IGFBP7 Q4 compared to in IGFBP7 Q1 tumors in (C) I-SPY2, and (D) SCAN-B. (D).

• Download figure
• Open in new tab

Figure 4.

Tumor microenvironment composition in relation to IGFBP7 gene expression Heatmap (A) of carcinoma ecotypes (CE), cell types, and cell states in patients (across all arms) in I-SPY2 whose tumors were assigned a dominant ecotype. Pearson correlations of IGFBP7 gene expression (continuous) and relative abundance of each CE. The dominant CE (C) in breast cancers by IGFBP7 quartiles.

Discussion

We report, using data from the I-SPY trial, that breast cancer patients with tumors showing low IGFBP7 gene expression had more than double the probability of achieving a pCR with neoadjuvant treatment using the combination of ganitumab, metformin, and chemotherapy than using neoadjuvant chemotherapy alone. In contrast, IGFBP7 expression was unrelated to the probability of chemotherapy alone achieving a pCR. To our knowledge, this is the first study to date that identifies a specific biomarker related to efficacy of IGF-1R targeting treatment. By the use of IGFBP7 as a predictor of ganitumab efficacy, we identified a substantial proportion of HER2 negative breast cancers including both poor prognosis HR⁺HER^- cancers (54.7% of patients) and TNBC (45.3% of patients) where the addition of ganitumab/metformin plus chemotherapy substantially improves pCR rates. Furthermore, we observed that high IGFBP7 expression was associated with worse clinical outcome in SCAN-B, a large contemporary population-based breast cancer cohort.

Our finding that low IGFBP7 expression defines a subset of patients where the addition of ganitumab to chemotherapy approximately doubles the pCR rate, shows the utility of the I-SPY2 trial design. Furthermore, our results demonstrate that detailed examination of the publicly available I-SPY2-990 Data Resource, either hypothesis-driven (as in this case), or agnostically, can provide opportunities to test hypotheses that were not proposed before or during the execution of the trial. The initial assessment of IGF signaling axis in the I-SPY2 ganitumab arm⁸ was negative but failed to include IGFBP7, a non-canonical IGFBP. Had IGFBP7 been included in the initial assessment of predictive biomarkers in I-SPY2, it would have identified the distinct subgroup where ganitumab showed benefit. Our findings add to the list of important studies^11,13–16 where the I-SPY2 trial detected activity of novel agents^10,11,15,16, even if the benefit is shown to be confined to a biomarker-defined subset of patients.

The molecular features of tumors with high IGFBP7 expression suggest an aggressive TME that facilitates metastasis. The ECOTYPER data suggest that strong evidence that IGFBP7 expression is a useful classifier distinct subtypes of the breast cancer microenvironment. This is consistent with previous studies showing that both systemic and tumor-specific IGFBP7 protein levels were poor prognostic markers in breast cancer^20,21, and are also in line with our results from SCAN-B. Despite early studies^17–21, there are many gaps in knowledge concerning the manner by which IGFBP7 modulates signaling by the IGF-1R family, and potentially the efficacy of anti-IGF-IR antibodies. Our findings provide a strong rationale for further experimental work to elucidate how IGFBP7 diminishes the effect of ganitumab and biological influence of IGFBP7 on the TME.

IGFBP7 merits further study as a treatment predictive biomarker in other cancer types such as colon, ovarian and prostate cancer, as well as sarcomas, where IGF-1R targeting agents have been investigated^4,31. We emphasize that the lack of data concerning HER2-positive breast cancers does not imply lack of activity in these patients; they simply were not eligible for the ganitumab arm of the I-SPY2 study because of non-availability of clinical safety data regarding co-administration of ganitumab and HER2 targeting agents. In fact, prior literature³² has suggested benefit of co-targeting IGF-IR and HER2 signaling.

The strengths of this study include the use of contemporary data from both the I-SPY2 trial and SCAN-B cohort. SCAN-B allows for the evaluation of biomarkers in a contemporary real-world setting due to the large-scale RNAseq analysis of consecutively enrolled breast cancer patients ^22–24. Further, I-SPY2 evaluates ganitumab in a randomized controlled setting, providing an ideal platform for investigation of treatment specific biomarkers for ganitumab. The IGFBP7 expression showed stable associations with clinicopathological factors and molecular features across SCAN-B and ISPY-2.

The current study, while hypothesis driven, is a retrospective analysis of existing datasets and thus the results require further validation in prospective studies. Future work should include investigation of circulating IGFBP7 in relation to ganitumab response, as we did not have access to ISPY-2 blood samples. Another limitation is the lack of data on long-term outcome in I-SPY2, but it has been previously shown that pCR has a strong association with distant metastasis-free survival³³. Due to the combination of ganitumab and metformin plus chemotherapy in the treatment arm, it is not possible to determine with certainty whether IGFBP7 expression identifies tumors sensitive to ganitumab alone, metformin alone or the combination. However, the MA.32 randomized clinical trial did not show benefit of adjuvant metformin compared to standard therapy in early-stage breast cancer³⁴, suggesting that the observed effect in I-SPY2 was driven by ganitumab.

There are few treatment options beyond chemotherapy in TNBC. Recently PARP inhibitors and immune checkpoint inhibitors have been incorporated in clinical practice^{10,11,16,35–37}. Ganitumab plus chemotherapy combinations have a fairly benign side effect profile ⁸, and may improve outcomes for TNBC and other cancers, provided that IGFBP7 is validated as predictive biomarker. The main side effect is temporary hyperglycemia which can be managed with metformin.

In conclusion, low IGFBP7 gene expression identifies a subset of breast cancers for whom the addition of ganitumab and metformin to neoadjuvant chemotherapy results in a significantly improved pCR rate compared to neoadjuvant chemotherapy alone. This justifies laboratory studies to address gaps in knowledge concerning roles of IGFBP7 in neoplasia, and the relevance of this protein to IGF-1R targeting agents. Such research, together with the results presented here, may lead to a review of decisions to halt the development of IGF-1 targeting drugs, which were based on disappointing results of prior trials that did not use predictive biomarkers.

Data and code availability

Clinical and RNA-seq data from SCAN-B is accessible from Staaf et al. ²⁴, available at Mendeley Data. The clinical and transcriptomic data from I-SPY2 are available from the GEO database (GSE194040). This paper does not report original code. Any additional information required to reanalyze the data reported in this paper is available upon request.

Ethics statement

Ethical approvals for I-SPY2 and SCAN-B were obtained in relation to the primary projects and publications ^{13,15,16,22–24}. No other separate approval was obtained for this specific study since it is based on previously published data. All participants signed written informed consent. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki.

Authors’ contributions

C Godina: Conceptualization, Data curation, Formal analysis, Methodology, Software, Resources, Visualization, Writing – original draft. MN Pollak: Conceptualization, Supervision, Writing – review & editing. H Jernström: Conceptualization, Funding acquisition, Formal analysis, Project administration, Supervision, Writing – original draft, Writing – review & editing. All authors have read and agreed to the published version of the manuscript.

Declaration of interests

The authors declare no competing interests.